新β‐アドレナリン様受容体しゃ断薬,dl‐1‐(第四ブチルアミノ)‐3‐[(2‐プロピニルオキシ)フェノキシ]‐2‐プロパノール塩酸(dlKoe1400‐Cl)の実験的抗不整脈効果

書誌事項

タイトル別名
  • Antiarrhythmic effects of dl-1-(tert. butylamino)-3-((2-propinyloxy)phenoxy)-2-propanol hydrochloride (Kö1400-Cl), a new adrenergic β-blocking agent.
  • シン ベータ adrenergic receptor blocking age

この論文をさがす

抄録

Antiarrhythmic property of a new adrenergic β-blocking agent, dl-1-(tert.butylamino)-3-C(2-propinyloxy) phenoxyj-2-propanol hydrochloride (Kö1400-Cl) was studied, using 1) ouabain-induced arrhythmia in the guinea pig, 2) aconitine-induced arrhythmia in the rat, 3) arrhythmia induced by two-step ligation of coronary artery (Harris's method) in the dog and 4) halothane-adrenaline arrhythmia in the dog and was compared with those of propranolol, oxprenolol, procainamide and ajmaline. Procainamide and ajmaline produced a marked protective effect against aconitine-induced ventricular extrasystole, but were not so effective against aconitine-induced ventricular fibrillation, while oxprenolol and, to a lesser degree, propranolol were effective against the latter type of aconitine arrhythmias. Kö1400-Cl proved to be ineffective. All the compounds tested produced a marked protective action against ouabain-arrhythmia. Whereas procainamide was most effective in abolishing the ventricular arrhythmia due to coronary-ligation even on the first postoperative day, Kö1400-Cl and propranolol were almost ineffective on the first day. Even on the second postoperative day, the antiarrhythmic effects of these two β-blockers were not remarkable, effective only in 2/4 animals in the case of Kö1400-Cl and in 2/3 animals in the case of propranolol. On the contrary, all the β-blockers tested produced a protective action against halothane-adrenaline arrhythmia at much lower doses than against coronary ligation arrhythmia. The potency ratio of Kö1400-Cl and propranolol was 3 : 1, which paralleled with β-blocking activity of these compounds.

収録刊行物

  • 日本薬理学雑誌

    日本薬理学雑誌 72 (5), 557-571, 1976

    公益社団法人 日本薬理学会

被引用文献 (3)*注記

もっと見る

キーワード

詳細情報

問題の指摘

ページトップへ